The COVID-19 pandemic has prompted researchers to find treatments and vaccines to control SARS-CoV-2. There are some hypotheses about the benefit of respiratory virus vaccines, like MMR, for COVID-19 pneumonia severity, morbidity, and mortality. The influenza vaccine is one of the most frequently used respiratory virus vaccines covered by one of the Iranian insurance institutes. We have a symmetrical group of participants that have received this vaccine that could be compared with each other. We compared 3,379 persons aged 20-75 years for the effect of the influenza vaccine on COVID-19 mortality. We ultimately found that it does not affect mortality caused by COVID-19 pneumonia, but it can decrease the hospitalization cost in people over 65 years with a history of chronic disease.
CITATION STYLE
Mosaed, R., Fasihi, H., Norouzi, A., Anjomanian, V., Ardalan, M. A., Noodeh, F. A., & Khoshdel, A. R. (2022). Influenza Vaccine and COVID-19 Pandemic: Could This Vaccine Help Limit the Potential Adverse Consequences of SARS-CoV-2? Iranian Journal of Pharmaceutical Research, 21(1). https://doi.org/10.5812/ijpr-127032
Mendeley helps you to discover research relevant for your work.